Research & Development



  霍光欽佩的看著劉據道︰“好辦法,不過,我以為只要把八百金放進水槽里,在水槽上劃一道線,取出八百金,再把無鹽氏的金球放進水槽里,只要無鹽氏金球……”   劉據一下子就來了興趣,走到霍光身邊,圍著他轉了一圈,霍光也跟著轉,就是不讓他看見自己哭過的樣子。99热99re99在线青青草   皇家拿走了雲氏生物技術,結果呢?大漢朝的農作物耕作技術,依舊是在刀耕火種。久久天天啪视频在线99   像他這樣的人年輕的時候鄙陋不堪,然而,越老就越有味道,最後讓人仰之彌高。   彼之蜜糖,我之砒霜說的就是這個道理。”米奇影音777第四色   只有那些地位足夠高,官職足夠大,名聲傳播的足夠遠的人,才知道跟劉徹打交道是一件多麼痛苦的事情。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo